Litchfield Hills Research Weighs in on ADIL Q1 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Analysts at Litchfield Hills Research boosted their Q1 2025 EPS estimates for Adial Pharmaceuticals in a note issued to investors on Tuesday, March 18th. Litchfield Hills Research analyst T. O’neill now anticipates that the company will earn ($0.37) per share for the quarter, up from their prior estimate of ($0.40). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.22) EPS.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.23.

Adial Pharmaceuticals Trading Down 1.7 %

Adial Pharmaceuticals stock opened at $0.72 on Thursday. The firm has a 50-day moving average of $0.83 and a 200-day moving average of $0.97. The firm has a market cap of $4.76 million, a P/E ratio of -0.22 and a beta of 1.13. Adial Pharmaceuticals has a 1-year low of $0.61 and a 1-year high of $3.10.

Institutional Trading of Adial Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC purchased a new stake in Adial Pharmaceuticals in the fourth quarter worth about $48,000. Citadel Advisors LLC lifted its holdings in Adial Pharmaceuticals by 63.8% in the fourth quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock worth $55,000 after buying an additional 21,238 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Adial Pharmaceuticals by 36.0% in the fourth quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock worth $62,000 after buying an additional 16,381 shares during the period. 16.41% of the stock is currently owned by hedge funds and other institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.